Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1995 Aug;71(838):498–500. doi: 10.1136/pgmj.71.838.498

Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.

M J Murphy 1, A Duncan 1, B D Vallance 1, C J Packard 1, D S O'Reilly 1
PMCID: PMC2398218  PMID: 7567762

Abstract

A significant reduction in plasma high density lipoprotein (HDL) cholesterol is a recognised consequence of treatment with probucol. By contrast, fibrate therapy in general has the opposite effect. We report two cases where the combination of probucol and a fibrate led to profoundly reduced plasma levels of HDL cholesterol associated with very low levels of apolipoprotein A-I (apoA-I). In the first, bezafibrate was added to probucol, and in the second, probucol added to a combination of simvastatin and fenofibrate. In both cases, plasma levels of HDL and apoA-I returned towards normal after discontinuation of one or both drugs, indicating that the reduction was reversible.

Full text

PDF
498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Lehtonen A., Viikari J. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia. Artery. 1982;10(5):353–367. [PubMed] [Google Scholar]
  2. Lock D. R., Kuisk I., Gonen B., Patsch W., Schonfeld G. Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover. Atherosclerosis. 1983 Jun;47(3):271–278. doi: 10.1016/0021-9150(83)90058-8. [DOI] [PubMed] [Google Scholar]
  3. McPherson R., Hogue M., Milne R. W., Tall A. R., Marcel Y. L. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb. 1991 May-Jun;11(3):476–481. doi: 10.1161/01.atv.11.3.476. [DOI] [PubMed] [Google Scholar]
  4. Micheli H., Pometta D., Gustafson A. Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm. 1979 Dec;17(12):503–506. [PubMed] [Google Scholar]
  5. Miettinen T. A., Huttunen J. K., Kuusi T., Kumlin T., Mattila S., Naukkarinen V., Strandberg T. Effect of probucol on the activity of postheparin plasma lipoprotein lipase and hepatic lipase. Clin Chim Acta. 1981 Jun 2;113(1):59–64. doi: 10.1016/0009-8981(81)90440-x. [DOI] [PubMed] [Google Scholar]
  6. Mordasini R., Riesen W., Oster P., Keller M., Middelhoff G., Lang P. D. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate. Atherosclerosis. 1981 Oct;40(2):153–158. doi: 10.1016/0021-9150(81)90033-2. [DOI] [PubMed] [Google Scholar]
  7. Nestel P. J., Billington T. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis. 1981 Jan-Feb;38(1-2):203–209. doi: 10.1016/0021-9150(81)90117-9. [DOI] [PubMed] [Google Scholar]
  8. Vessby B., Lithell H., Hellsing K., Ostlund-Lindqvist A. M., Gustafsson I. B., Boberg J., Ledermann H. Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters. Atherosclerosis. 1980 Oct;37(2):257–269. doi: 10.1016/0021-9150(80)90011-8. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES